Rivaroxaban

Green-G

Brand Name(s):Xarelto

Indication:Stroke and systemic embolism (prevention of) in adult patients with non-valvular atrial fibrillation with one or more risk factors

Rationale:

Considered:Nov-11

Review Date:Aug-24

Comments:
Drug Safety Update
Rivaroxaban : reminder that 15 mg and 20 mg tablets should be taken with food
Jul-19
…………………………
Drug Safety Update
Rivaroxaban treatment in patients who undergo transcatheter aortic valve replacement (TAVR) should be stopped and switched to standard of care.
Oct-18
…………………………
Refer to Formulary Guidelines
Apixaban is the first line formulary choice of DOAC for patients with Non Valvular AF
…………………………

Risk of haemorrhage
Prescribers should note guidance issued by MHRA regarding risk of serious haemorrhage with the new oral anticoagulant drugs (NOAC’s). Guidance contains updated information on contraindications and warnings for use.

MHRA guidance available at: http://www.mhra.gov.uk/home/groups/pl-p/documents/drugsafetymessage/con321961.pdf
Issued October 2013
…………………………

Pulmonary embolism and recurrent venous thromboembolism – rivaroxaban: guidance –
NICE TA287 Pulmonary embolism and recurrent venous thromboembolism – rivaroxaban: guidance
Issued June 2013